INVEGA (Paliperidone): Uses, Dosage & Side Effects
Extended-release paliperidone tablets for schizophrenia and schizoaffective disorder
INVEGA (paliperidone) is an atypical (second-generation) antipsychotic medication prescribed for the treatment of schizophrenia in adults and adolescents aged 15 years and older, and schizoaffective disorder in adults. It works by modulating dopamine and serotonin activity in the brain. INVEGA uses an innovative osmotic-controlled release oral delivery system (OROS) that provides consistent drug levels over 24 hours, allowing once-daily dosing. This guide covers uses, dosage, side effects, drug interactions, and important safety information based on international clinical guidelines.
Quick Facts About INVEGA
Key Takeaways About INVEGA
- Primary indications: INVEGA treats schizophrenia (adults and adolescents 15+) and schizoaffective disorder (adults), helping to control hallucinations, delusions, disorganised thinking, and mood disturbances.
- Unique delivery system: INVEGA uses OROS technology, an osmotic-controlled release system. Tablets must be swallowed whole and the empty shell passes harmlessly in the stool.
- Metabolic monitoring is essential: Regular monitoring of weight, blood glucose, and lipid levels is recommended throughout treatment, as INVEGA can cause metabolic changes.
- Prolactin elevation is common: INVEGA frequently raises prolactin levels, which may cause menstrual irregularities, breast enlargement, or sexual dysfunction. Discuss any symptoms with your doctor.
- Not for elderly patients with dementia: INVEGA is not approved for dementia-related psychosis in elderly patients due to increased risk of cerebrovascular adverse events and death.
What Is INVEGA and What Is It Used For?
INVEGA (paliperidone) is an atypical antipsychotic belonging to the benzisoxazole derivative class. It is the major active metabolite of risperidone and is approved for the treatment of schizophrenia in adults and adolescents aged 15 years and older, as well as schizoaffective disorder in adults.
Paliperidone exerts its therapeutic effects primarily by blocking dopamine D2 receptors and serotonin 5-HT2A receptors in the central nervous system. This dual mechanism of action helps to reduce both the positive symptoms of psychosis (such as hallucinations, delusions, and disorganised thinking) and the negative symptoms (such as social withdrawal, emotional flatness, and lack of motivation). Additionally, paliperidone has antagonist activity at alpha-1 and alpha-2 adrenergic receptors and histamine H1 receptors, which contributes to some of its side effects.
INVEGA is formulated as an extended-release tablet using the osmotic-controlled release oral delivery system (OROS). This innovative technology ensures that the active ingredient is released gradually and consistently over a 24-hour period, maintaining stable plasma drug concentrations. The OROS system works by using osmotic pressure to push the drug through a laser-drilled hole in the tablet shell. After the active substance is fully released, the inert tablet shell is eliminated intact in the stool, which is entirely normal and not a cause for concern.
Schizophrenia
Schizophrenia is a chronic and severe mental disorder affecting approximately 1% of the global population. It is characterised by a range of symptoms that can be broadly grouped into positive symptoms (hallucinations, delusions, disorganised speech and behaviour), negative symptoms (diminished emotional expression, avolition, social withdrawal, anhedonia), and cognitive symptoms (impaired attention, working memory, and executive function). INVEGA has demonstrated efficacy in reducing all symptom domains in both short-term and long-term clinical trials.
In clinical studies, paliperidone extended-release has shown statistically significant improvements on the Positive and Negative Syndrome Scale (PANSS) compared to placebo. The medication is effective as both acute treatment for psychotic episodes and as maintenance therapy to prevent relapse. According to the Lancet meta-analysis by Huhn et al. (2019), paliperidone ranked among the effective oral antipsychotics for the treatment of schizophrenia, with a favourable balance between efficacy and tolerability.
Schizoaffective Disorder
Schizoaffective disorder is a complex psychiatric condition that combines features of both schizophrenia and a mood disorder (either bipolar type or depressive type). Patients with this condition experience psychotic symptoms characteristic of schizophrenia alongside significant mood episodes, including mania, depression, or both. INVEGA is approved for the treatment of schizoaffective disorder in adults, where it addresses both the psychotic and mood components of the illness.
Clinical trials have demonstrated that paliperidone extended-release significantly reduced both the psychotic and mood symptom domains in patients with schizoaffective disorder. The recommended dosage range for schizoaffective disorder is 6 mg to 12 mg once daily, which is slightly higher than the starting dose for schizophrenia, reflecting the need to address the additional mood symptom burden.
What Should You Know Before Taking INVEGA?
Before starting INVEGA, inform your doctor about all medical conditions, medications, and allergies. Several conditions require special monitoring or may contraindicate use of this medication. INVEGA is not recommended in elderly patients with dementia-related psychosis.
Contraindications
You must not take INVEGA if you are allergic (hypersensitive) to paliperidone, risperidone, or any of the other ingredients in the tablets. Since paliperidone is the active metabolite of risperidone, patients with known hypersensitivity to risperidone should also avoid INVEGA. Allergic reactions can range from skin rashes to severe anaphylaxis with facial swelling, difficulty breathing, and a drop in blood pressure.
Warnings and Precautions
Talk to your doctor before taking INVEGA if you have any of the following conditions, as they may require dose adjustment, additional monitoring, or alternative treatment:
- Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening condition characterised by high fever, severe muscle rigidity, altered consciousness, and autonomic instability. Stop INVEGA immediately and seek emergency care.
- Tardive Dyskinesia: Involuntary rhythmic movements of the tongue, face, and jaw that may become permanent. Report any unusual movements to your doctor promptly.
- Blood Clots: Antipsychotics have been associated with venous thromboembolism (blood clots), particularly in the legs, which can travel to the lungs and be life-threatening.
- Priapism: Prolonged and painful erection that requires immediate medical intervention to prevent permanent damage.
Additional conditions requiring caution include:
- Parkinson's disease or dementia: INVEGA may worsen motor symptoms and cognitive decline.
- Cardiovascular disease: Including conditions that predispose to low blood pressure (orthostatic hypotension), heart rhythm abnormalities (QT prolongation), or history of cardiac arrhythmias.
- Diabetes or risk factors for diabetes: INVEGA can cause hyperglycaemia and worsen existing diabetes. Regular blood glucose monitoring is essential.
- Epilepsy or history of seizures: Antipsychotics may lower the seizure threshold.
- Kidney problems: Dose adjustment is required in patients with renal impairment. INVEGA is not recommended in severe renal impairment.
- Liver problems: While paliperidone undergoes minimal hepatic metabolism, caution is advised in patients with significant liver disease.
- Gastrointestinal narrowing: Since INVEGA uses a non-deformable extended-release system, it should not be used in patients with severe gastrointestinal narrowing (pathological or iatrogenic) or conditions involving impaired swallowing or gastrointestinal motility.
- Hyperprolactinaemia: If you have conditions associated with elevated prolactin levels or prolactin-dependent tumours, discuss this with your doctor.
- Body temperature regulation: Antipsychotics can impair thermoregulation. Avoid extreme heat exposure and ensure adequate hydration.
- History of blood clots: Inform your doctor if you or a family member have a history of venous thromboembolism.
In rare cases, INVEGA has been associated with dangerously low levels of certain white blood cells (agranulocytosis), which can impair your ability to fight infections. Your doctor may periodically check your blood count during treatment. Contact your doctor immediately if you develop signs of infection such as fever, sore throat, or mouth ulcers.
Cataract Surgery
If you are planning to have cataract surgery, inform your ophthalmologist that you are taking or have previously taken INVEGA. During cataract surgery, a condition called Intraoperative Floppy Iris Syndrome (IFIS) may occur, where the pupil does not dilate adequately and the iris may become floppy. This information allows the surgeon to take appropriate precautions to prevent eye damage.
Children and Adolescents
INVEGA is approved for the treatment of schizophrenia in adolescents aged 15 years and older. It is not approved for use in children under 15 years for schizophrenia, and it is not approved for children or adolescents under 18 years for schizoaffective disorder. The safety and efficacy of INVEGA have not been established in these younger age groups.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your doctor before taking INVEGA. INVEGA should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.
Newborns exposed to antipsychotic medications (including paliperidone) during the third trimester of pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms after delivery. These may include tremor, muscle stiffness or weakness, sleepiness, agitation, breathing difficulties, and feeding problems. If your baby develops any of these symptoms, contact your healthcare provider.
Paliperidone is excreted in human breast milk. Breastfeeding is not recommended during treatment with INVEGA due to the potential for adverse effects in the nursing infant.
Driving and Operating Machinery
INVEGA may cause dizziness, visual disturbances, and somnolence, which can impair your ability to drive or operate machinery. Do not drive or engage in activities requiring full alertness until you know how INVEGA affects you.
How Does INVEGA Interact with Other Drugs?
INVEGA can interact with several medications, including those that affect the heart's electrical activity, central nervous system depressants, blood pressure medications, and drugs that alter gastrointestinal motility. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking.
Since INVEGA primarily acts on the central nervous system, combining it with other CNS-active substances may result in enhanced effects. Alcohol should be strictly avoided during treatment with INVEGA, as the combination can intensify sedation and impair cognitive and motor function.
Major Interactions
| Interacting Drug | Type | Effect | Action Required |
|---|---|---|---|
| Carbamazepine and other strong CYP3A4/P-gp inducers | Pharmacokinetic | Reduced paliperidone exposure by up to 37%, potentially reducing efficacy | INVEGA dose increase may be required; re-evaluate when inducer is discontinued |
| QT-prolonging medications (e.g. certain antiarrhythmics, antihistamines, antimalarials, other antipsychotics) | Pharmacodynamic | Increased risk of QT prolongation and potentially fatal cardiac arrhythmias | Avoid combination or use with extreme caution; ECG monitoring recommended |
| Oral risperidone | Pharmacodynamic | Combined exposure to paliperidone (as INVEGA is the active metabolite of risperidone), increasing risk of side effects | Not recommended to use together |
| Levodopa and other dopamine agonists | Pharmacodynamic | Mutual antagonism; INVEGA may reduce the effects of Parkinson's disease medications | Avoid combination if possible; if used, careful dose adjustment needed |
| Antihypertensive medications | Pharmacodynamic | Additive blood pressure lowering, increasing risk of orthostatic hypotension | Monitor blood pressure closely; adjust doses as needed |
Other Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Valproate | May increase paliperidone exposure; clinical significance varies | Consider dose reduction of INVEGA when used concurrently |
| Metoclopramide and other prokinetic agents | May alter the rate of paliperidone release from the OROS system | Use with caution; monitor for altered drug effect |
| Psychostimulants (e.g. methylphenidate) | CNS stimulants may interact unpredictably with antipsychotics | Use with caution; monitor for clinical effects |
| Alcohol | Enhanced CNS depression, increased sedation, impaired judgement | Avoid alcohol during treatment |
Importantly, paliperidone undergoes minimal hepatic metabolism (unlike risperidone), and therefore has a lower potential for pharmacokinetic drug interactions involving cytochrome P450 enzymes. However, it is a substrate of P-glycoprotein (P-gp), meaning drugs that strongly induce or inhibit P-gp transport may affect paliperidone exposure. Strong CYP3A4 and P-gp inducers such as carbamazepine, rifampicin, and St John's Wort may significantly reduce paliperidone levels and should be used with caution.
What Is the Correct Dosage of INVEGA?
The recommended starting dose of INVEGA for adults with schizophrenia is 6 mg once daily, taken in the morning. The dose can be adjusted within the range of 3 mg to 12 mg once daily based on individual clinical response and tolerability. For schizoaffective disorder, the recommended range is 6 mg to 12 mg once daily.
Adults
Schizophrenia (Adults)
Recommended starting dose: 6 mg once daily, taken in the morning.
Dose range: 3 mg to 12 mg once daily.
Dose adjustments, if needed, should be made at intervals of at least 5 days. The maximum recommended dose is 12 mg per day. Some patients may benefit from a lower starting dose of 3 mg per day.
Schizoaffective Disorder (Adults)
Recommended starting dose: 6 mg once daily, taken in the morning.
Dose range: 6 mg to 12 mg once daily.
The dose may be increased based on clinical response and tolerability. The maximum recommended dose is 12 mg per day.
Adolescents (15 Years and Older)
Schizophrenia (Adolescents 15+)
Recommended starting dose: 3 mg once daily, taken in the morning.
Dose range for patients weighing 51 kg or more: 3 mg to 12 mg once daily.
Dose range for patients weighing less than 51 kg: 3 mg to 6 mg once daily.
Dose adjustments should be made based on clinical response and tolerability. INVEGA is not approved for adolescents with schizoaffective disorder.
Patients with Kidney Problems
Renal Impairment Dosing
Since paliperidone is predominantly eliminated by the kidneys, dose adjustment is necessary in patients with renal impairment:
- Mild impairment (CrCl 50-79 mL/min): Maximum dose 6 mg once daily
- Moderate impairment (CrCl 10-49 mL/min): Maximum dose 3 mg once daily
- Severe impairment (CrCl <10 mL/min): Not recommended
Elderly Patients
In elderly patients with normal kidney function, no dose adjustment is required. However, if an elderly patient has impaired kidney function, the dose should be adjusted according to the renal impairment guidelines above. Elderly patients should be monitored carefully for orthostatic hypotension due to increased sensitivity.
How to Take INVEGA
- Swallow tablets whole with water or another beverage
- Do NOT chew, break, or crush the tablets
- Take once daily in the morning
- Take consistently either with breakfast or without breakfast each day (do not alternate)
- The empty tablet shell will pass in your stool — this is normal
Missed Dose
If you miss a dose, do not take a double dose to make up for it. If you miss one dose, take the next dose the day after the missed dose. If you miss two or more consecutive doses, contact your doctor for guidance on how to restart the medication.
Overdose
If you take too much INVEGA, contact your doctor or emergency services immediately. Symptoms of overdose may include drowsiness, sedation, abnormal involuntary movements, difficulty standing and walking, dizziness (from low blood pressure), and abnormal heart rhythm (tachycardia). There is no specific antidote for paliperidone overdose; treatment is supportive and symptomatic.
Do not stop taking INVEGA without consulting your doctor, even if you feel better. Sudden discontinuation can cause your symptoms to return. Your doctor may recommend gradually reducing the dose if discontinuation is appropriate.
What Are the Side Effects of INVEGA?
Like all medicines, INVEGA can cause side effects, although not everyone experiences them. The most commonly reported side effects include headache, insomnia, parkinsonism (slow movements, muscle stiffness), akathisia (restlessness), and somnolence (drowsiness). Most side effects are dose-related and may improve with dose adjustment.
Contact your doctor immediately if you experience any of the following serious side effects: blood clots (swelling, pain and redness in the legs, chest pain, difficulty breathing), signs of stroke (sudden weakness, numbness, slurred speech), neuroleptic malignant syndrome (high fever, severe muscle rigidity, altered consciousness), priapism (prolonged painful erection), severe allergic reactions (fever, swelling of mouth, face or throat, difficulty breathing, skin rash), or involuntary rhythmic movements of the tongue, mouth, or face (tardive dyskinesia).
Very Common
- Difficulty falling asleep or staying asleep (insomnia)
- Parkinsonism: slow or impaired movement, muscle stiffness, tremor, shuffling gait, drooling, loss of facial expression
- Akathisia: a feeling of restlessness and inability to sit still
- Somnolence: feeling drowsy or less alert
- Headache
Common
- Upper respiratory tract infections, sinusitis, urinary tract infections, influenza-like illness
- Weight gain, increased or decreased appetite
- Mania (elevated mood), irritability, depression, anxiety
- Dystonia: involuntary sustained muscle contractions affecting any body part
- Dizziness, dyskinesia (involuntary movements), tremor
- Blurred vision
- Heart conduction abnormalities, QT prolongation, slow or fast heartbeat
- Low blood pressure on standing (orthostatic hypotension), high blood pressure
- Sore throat, cough, nasal congestion
- Abdominal discomfort, nausea, vomiting, constipation, diarrhoea, dry mouth, toothache
- Elevated liver enzymes (transaminases)
- Itching, skin rash
- Bone or muscle pain, back pain, joint pain
- Absent menstrual periods
- Fever, weakness, fatigue
Uncommon
- Pneumonia, bladder infection, ear infection, tonsillitis
- Decreased white blood cells, decreased platelets, anaemia
- Elevated prolactin levels (may cause breast enlargement, menstrual irregularities, milk discharge, sexual dysfunction in both sexes)
- Diabetes or worsening diabetes, high blood sugar, increased waist circumference, high triglycerides
- Sleep disturbances, confusion, decreased libido, inability to achieve orgasm, nightmares
- Tardive dyskinesia: involuntary jerky movements of face, tongue, or other body parts
- Seizures, fainting, restless legs, vertigo, attention difficulties, speech difficulties, taste disturbance
- Sensitivity to light, dry eyes, eye infection
- Ringing in the ears (tinnitus), ear pain
- Irregular heartbeat, palpitations
- Shortness of breath, wheezing, nosebleeds
- Swollen tongue, difficulty swallowing, excessive flatulence
- Hives (urticaria), hair loss, eczema, acne
- Elevated creatine kinase, muscle spasms, joint stiffness, joint swelling, muscle weakness
- Urinary incontinence, frequent urination, inability to urinate, painful urination
- Erectile dysfunction, ejaculation disorders
- Breast pain, milk leakage from breasts, sexual dysfunction
- Facial, limb, or body swelling
- Chills, increased body temperature, thirst, chest pain, falls
Rare
- Eye infection, nail fungus, skin infection, skin inflammation caused by mites
- Agranulocytosis: dangerously low white blood cell count, increasing susceptibility to infections
- Severe allergic reactions (anaphylaxis) with fever, swollen mouth, face, or tongue, difficulty breathing
- Neuroleptic malignant syndrome (NMS): confusion, reduced consciousness, high fever, severe muscle rigidity
- Sugar in the urine, abnormal antidiuretic hormone levels, dangerously excessive water intake
- Sleepwalking, catatonia (immobility and unresponsiveness), lack of emotions
- Loss of consciousness, balance disorder, head tremor, glaucoma
- Atrial fibrillation, rapid heartbeat on standing, blood clots in legs or lungs (potentially life-threatening)
- Sleep apnoea, rapid shallow breathing, lung inflammation from food aspiration
- Bowel obstruction, faecal incontinence, very hard stools, pancreatitis
- Jaundice (yellowing of skin and eyes)
- Rhabdomyolysis: breakdown of muscle fibres causing muscle pain
- Priapism: prolonged penile erection that may require surgery
- Breast development in men, breast enlargement, vaginal discharge
- Very low body temperature, withdrawal symptoms on discontinuation
Not Known Frequency
- Pulmonary embolism (blockage of blood flow in the lungs)
- Increased insulin levels
- Sleep-related eating disorder
- Stevens-Johnson syndrome or toxic epidermal necrolysis (serious skin reactions with blisters and peeling)
- Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery
Adolescents generally experienced similar side effects as adults. However, the following were more frequently observed in adolescents: somnolence/sedation, parkinsonism, weight gain, common cold symptoms, restlessness, tremor, abdominal pain, milk leakage from breasts (girls), breast swelling (boys), acne, speech difficulties, gastrointestinal infections, nosebleeds, ear infections, elevated triglycerides, and vertigo.
How Should You Store INVEGA?
Store INVEGA at or below 30°C (86°F) in the original packaging to protect from moisture. Keep out of the sight and reach of children.
INVEGA should be stored according to the specific packaging type:
- Bottles: Store at or below 30°C. Keep the container tightly closed. The product is moisture-sensitive.
- Blister packs: Store at or below 30°C. Keep in the original packaging. The product is moisture-sensitive.
Do not use INVEGA after the expiry date printed on the blister pack, bottle, or carton after "EXP". The expiry date refers to the last day of the stated month. Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use, as these measures help protect the environment.
What Does INVEGA Contain?
The active ingredient in INVEGA is paliperidone, available in four strengths: 3 mg, 6 mg, 9 mg, and 12 mg extended-release tablets. The tablets contain various inactive ingredients that form the osmotic-controlled release delivery system.
Each INVEGA extended-release tablet contains paliperidone as the active substance. The tablets are capsule-shaped and can be identified by their colour and marking:
| Strength | Colour | Imprint |
|---|---|---|
| 3 mg | White | PAL 3 |
| 6 mg | Beige | PAL 6 |
| 9 mg | Pink | PAL 9 |
| 12 mg | Dark yellow | PAL 12 |
The inactive ingredients include polyethylene oxide, sodium chloride, povidone, stearic acid, butylated hydroxytoluene (E321), iron oxide pigments (yellow E172, red E172, black E172 depending on strength), hydroxyethyl cellulose, polyethylene glycol, cellulose acetate, hypromellose, titanium dioxide (E171), triacetin, lactose monohydrate (3 mg tablet only), carnauba wax, and printing ink containing iron oxide black (E172), propylene glycol, and hypromellose.
The 3 mg tablet contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine. All INVEGA tablets contain less than 1 mmol (23 mg) sodium per tablet, meaning they are essentially sodium-free.
INVEGA is available in bottles containing 30 or 350 tablets (with two silica gel desiccant sachets to absorb moisture) and in blister packs of 14, 28, 49, 56, and 98 tablets. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About INVEGA
INVEGA (paliperidone) is an atypical antipsychotic used to treat schizophrenia in adults and adolescents aged 15 years and older, and schizoaffective disorder in adults. It helps manage symptoms including hallucinations, delusions, disorganised thinking, suspiciousness, social withdrawal, and mood disturbances. The medication works by modulating dopamine and serotonin signalling in the brain.
The most common side effects (affecting more than 1 in 10 people) include insomnia, headache, parkinsonism (slow movements, muscle stiffness, tremor), akathisia (restlessness), and somnolence (drowsiness). Common side effects also include weight gain, dizziness, dystonia, nausea, constipation, and elevated prolactin levels. Most side effects are manageable and may improve with dose adjustment.
INVEGA tablets must be swallowed whole with water or another beverage. They must not be chewed, broken, or crushed, as this would destroy the osmotic delivery system. Take the tablet once daily in the morning, consistently either with or without breakfast. The empty tablet shell passes in the stool, which is perfectly normal.
Yes, weight gain is a common side effect of INVEGA. Your doctor should regularly monitor your weight during treatment. Maintaining a healthy diet and engaging in regular physical activity can help manage weight. If weight gain becomes excessive, your doctor may consider adjusting your dose or switching to an alternative medication. INVEGA can also affect blood sugar and lipid levels, so metabolic monitoring is important.
INVEGA should not be used during pregnancy unless clearly necessary and the benefits outweigh the risks. Newborns exposed to antipsychotics during the third trimester may experience tremor, muscle stiffness, weakness, sleepiness, agitation, breathing problems, and feeding difficulties. Breastfeeding is not recommended during INVEGA treatment as the drug passes into breast milk. Always discuss pregnancy planning and contraception with your doctor.
Paliperidone (the active ingredient in INVEGA) is the major active metabolite of risperidone. Both medications share a similar mechanism of action, but paliperidone undergoes minimal liver metabolism, making it potentially less susceptible to drug interactions involving hepatic enzymes. INVEGA also uses an extended-release delivery system for more consistent blood levels. Importantly, oral risperidone should not be taken concurrently with INVEGA, as the combination increases the risk of adverse effects.
References
- European Medicines Agency (EMA). INVEGA (paliperidone) – Summary of Product Characteristics. EMA/EPAR. Updated 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). INVEGA (paliperidone) Extended-Release Tablets – Prescribing Information. Janssen Pharmaceuticals, Inc. Updated 2024.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;394(10202):939-951. doi:10.1016/S0140-6736(19)31135-3
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Nussbaum AM, Stroup TS. Paliperidone extended-release: a review of its use in the management of schizophrenia. Drugs. 2012;72(8):1045-1063.
- British National Formulary (BNF). Paliperidone. National Institute for Health and Care Excellence. Updated 2025.
- Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol. 2010;30(5):487-495.
- Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia. J Clin Psychopharmacol. 2007;27(1):6-14.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Available at: who.int
- American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Schizophrenia. 3rd ed. Washington, DC: APA; 2020.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in clinical pharmacology, psychiatry, and internal medicine.
Content developed by medical professionals with expertise in psychopharmacology and psychiatric therapeutics, based on current international guidelines and peer-reviewed literature.
All content independently reviewed by the iMedic Medical Review Board for accuracy, completeness, and clinical relevance according to EMA, FDA, NICE, and WHO standards.
Information is based on Level 1A evidence (systematic reviews and meta-analyses of randomised controlled trials) following the GRADE evidence framework.
iMedic maintains full editorial independence with no pharmaceutical company sponsorship, advertising, or commercial funding. All content is produced solely in the interest of patient education.